Enhanced Anti-Cancer Capability of Ellagic Acid Using Solid Lipid Nanoparticles
Enhanced Anti-Cancer Capability of Ellagic Acid Using Solid Lipid Nanoparticles
نویسندگان: حامد حاجی پور , حامد همیشه کار , محمد رحمتی , داریوش شانه بندی , سعید نظری سلطان احمد , اکبر حسنی
کلمات کلیدی: Ellagic Acid, Prostate Cancer, Solid Lipid Nanoparticles, Cancer, Solid Lipid Nanoparticles; Cancer; SLN
نشریه: 0 , 1 , 11 , 2018
| نویسنده ثبت کننده مقاله |
اکبر حسنی |
| مرحله جاری مقاله |
تایید نهایی |
| دانشکده/مرکز مربوطه |
مرکز تحقیقات کاربردی دارویی |
| کد مقاله |
62689 |
| عنوان فارسی مقاله |
Enhanced Anti-Cancer Capability of Ellagic Acid Using Solid Lipid Nanoparticles |
| عنوان لاتین مقاله |
Enhanced Anti-Cancer Capability of Ellagic Acid Using Solid Lipid Nanoparticles |
| ناشر |
6 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ |
بلی |
| عنوان نشریه (خارج از لیست فوق) |
International journal of cancer management |
| نوع مقاله |
Original Article |
| نحوه ایندکس شدن مقاله |
ایندکس شده سطح سه – Scopus |
| آدرس لینک مقاله/ همایش در شبکه اینترنت |
|
| Background: Ellagic acid (EA) is a polyphenol, whose anti-cancer properties have been demonstrated in several cancer studies, but
the poor water solubility and low bioavailability have limited its therapeutic potential.
Objectives: The present study proposed to develop solid lipid nanoparticles (SLNs) as a delivery system for improving the anticancer
capability of EA on prostate cancer cell line.
Methods: EA-loaded SLNs were prepared by hot homogenization technique and characterized by different techniques. Cytotoxicity
of EA and EA-loaded SLNs on prostate cancer cell line (PC3) was evaluated by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) assay, and nucleus condensation, or chromatin fragmentation (the signs of apoptosis) were studied by 4’-6-
diamidino-2-phenylindole (DAPI) staining. The expression of B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax), which
are involved in apoptosis, were evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR).
Results: The nanoparticles with appropriate characteristics (particle size of 96 nm and Encapsulation Efficiency of 88%) were prepared.
The in vitro drug release profile showed a burst release in the first hours and followed by a sustained EA release until 72 hours.
EA-loaded SLNs displayed a good stability for 4 weeks of storage at 4 - 8°C. Cytotoxicity evaluations demonstrated that EA-loaded SLNs
prevented prostate cancer cells growth in a low IC50 value compared to the EA. The results of qRT-PCR demonstrated that EA causes
up-regulation of Bax and this regulation intensified when EA was loaded into SLNs, but there was no punctual correlation between
the EA and EA-loaded SLNs in down-regulation of Bcl-2.
Conclusions: The results strengthen our hope that loading EA into SLNs could possibly overcome the therapeutic limitations of EA
and make it more effective in prostate cancer therapy. |
| نام فایل |
تاریخ درج فایل |
اندازه فایل |
دانلود |
| hajipour.pdf | 1397/01/28 | 4470862 | دانلود |